Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: A review of current literature

Lung Cancer

Volumn 64, Issue 2, 2009, Pages 131-139

  Vilmar, Adam ^a   Sørensen, Jens Benn ^a  

^a FINSEN LABORATORY   (Denmark)

Author keywords

Carboplatin; Cisplatin; ERCC1; NSCLC; Predictive markers; Prognostic markers

Indexed keywords

CARBOPLATIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; OXALIPLATIN; TRIFLURIDINE;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; HUMAN; IMMUNOCHEMISTRY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STOMACH CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; HUMANS; LUNG NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 63049110664     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.08.006     Document Type: Review

References (42)

1. Ardizzoni A., Boni L., Tiseo M., Fosella F.V., Schiller J.H., Paesmans M., et al. Cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data analysis. J Natl Inst 99 (2007) 847-857
2. Olaussen K., Dunant A., Fouret P., Brambilla E., André F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 335 (2006) 983-991
3. Cobo M., Isla D., Massuti B., Montes A., Sanchez J.M., Provencio M., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25 (2007) 2747-2754
4. Darcy K., Tian C., and Reed E. A gynecologic oncology group study of platinum-DNA adducts and excision repair cross complementation group 1 expression in optimal, stage III ovarian cancer treated with platinum-taxane chemotherapy. Cancer Res 67 9 (2007) 4474-4481
5. Smith S., Su D., Rigault de la Longrais I., Schwartz P., Puopolo M., Rutherford T.J., et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 25 (2007) 5172-5179
6. Chung H., Kim M., Kim J., Park N.H., Song Y.S., Kang S.B., et al. XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer. Gyn Oncol 103 (2006) 1031-1037
7. Codegoni A.M., Broggini M., Pitelli M.R., Pantarotto M., Torri V., Mangioni C., et al. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gyn Oncol 65 (1997) 130-137
8. Kwon H., Roh M., Oh S., Oh Y., Kim S.H., Kim M.C., et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-flourouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 18 (2007) 504-509
9. Ruzzo A., Graziano F., Loupakis F., Rulli E., Canestrari E., Santini D., et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25 (2007) 1247-1254
10. Stoehlmacher J., Park D.J., Zhang W., Yang D., Groshen S., Zahedy S., et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Brit J Cancer 91 (2004) 344-354
11. de Laat W.L., Jaspers N.G., Hoeijmakers J., et al. Molecular mechanism of nucleotide excision repair. Genes Dev 13 (1999) 768-785
12. Wijnhoven S.W., Hoogervorst E.M., de Ward H., van der Horst G.T., and Steeg H. Tissue specific mutagenic and carcinogenic responses in NER defective mouse models. Mutat Res 614 (2007) 77-94
13. Trispsianes K., Folkers G., Ab E., Dus D., Odijk H., Jasper N.G., et al. The structure of the human ERCC1/XPF interaction domains reveals a complementary role for the two proteins in nucleotide excision repair. Structure 13 (2005) 1849-1858
14. Cummings M., Higgibottom K., McGurk C.J., Wong O.G., Köberle B., Oliver R.T., et al. XPA versus ERCC1 as chemosensitizing agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair. Biochem Pharmacol 72 (2006) 166-175
15. Youn C.K., Kim M.H., Cho H.J., Kim H.B., Chang I.Y., Chung M.H., et al. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents. Cancer Res 64 (2004) 4849-4857
16. Yu J.J., Mu C., Lee K.B., Okamoto A., Reed E.L., Bostick-Bruton F., et al. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumour tissues. Mut Res Gen 382 (1997) 13-20
17. Viguier J., Boige V., Miquel C., Pocard M., Giraudeau B., Sabourin J.C., et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumour response to oxaliplatin/5-flourouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11 17 (2005) 6212-6217
18. Shirota Y., Stoehlmacher J., Brabender J., Xiong Y.P., Uetake H., Danenberg K.D., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19 23 (2001) 4298-4304
19. Monzo M., Moreno I., Navarro A., Ibeas R., Artells R., Gel B., et al. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/flouropyrimidine. Oncology 72 (2007) 364-370
20. Kondo K, Fujino H, Takizawa H, Miyoshi T, Hirose Y, Nagao T, et al. ERCC1 expression is one of prognostic factors in completely resected non-small cell lung cancer patients with an adjuvant-platinum based chemotherapy. 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007. J Thorac Oncol 2(8) Suppl. 4:S646;2007.
21. Ryu J.S., Hong Y.C., Han H.S., Lee J.E., Kim S., Park Y.M., et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44 (2004) 311-316
22. Ceppi P., Volante M., Novello S., Rapa I., Danenberg K.D., Danenberg P.V., et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17 (2006) 1818-1825
23. Lord R., Brabender J., Gandara D., Alberola V., Camps C., Domine M., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8 (2002) 2286-2291
24. Booton R., Ward T., Ashcroft L., Morris J., Heighway J., and Thatcher N. ERCC1 is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2 (2007) 902-906
25. Wathers F.M., Wong L.S.M., Timens W., Kampinga H.H., and Groen H.J.M. ERCC1, hRAD51 and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 50 (2005) 211-219
26. Isla D., Sarries C., Rosell R., Alonso G., Domine M., Taron M., et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15 (2004) 1194-1203
27. Lee H.W., Han J.H., Kim J.H., Hee Lee M., Jeong S.H., Kang S.Y., et al. Expression of excision cross complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer 59 1 (2008) 95-104
28. Simon G., Sharma A., Li X., Hazelton T., Walsh F., Williams C., et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 25 (2007) 2741-2746
29. Bepler G., Kusmartseva I., Sharma S., Gautam A., Cantor A., Sharma A., et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non small cell lung cancer. J Clin Oncol 24 (2006) 4731-4737
30. Azuma K., Komohara Y., Sasada T., Terazaki Y., Ikeda J., Hoshino T., et al. Excision repair cross complementation group 1 predicts progression free survival and overall survival in non-small cell lung cancer patients treated with platinum based chemotherapy. Cancer Sci 98 9 (2007) 1336-1343
31. Zheng Z., Chen T., Li X., Haura E., Sharma A., Bepler S., et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356 (2007) 800-808
32. Eikmans M., Baelde H., de Heer E., and Bruijn J. Messenger RNA assessment in clinical nephrology: perspectives and progress of methodology. Nephrol Dial Transplant 20 (2005) 2598-2601
33. Chowdary D., Lathrop J., Skelton J., Curtin K., Briggs T., Zhang Y., et al. prognostic gene expression signatures can be measured in tissues collected in RNAlater preservatives. JMD 8 (2006) 31-39
34. Inoue T., Nabeshima K., Kataoka H., and Koono M. feasibility of archival non buffered formalin fixed and parafin embedded tissues for PCR amplification: an analysis of resected gastric carcinoma. Pathol Int 46 (1996) 997-1004
35. Britten A., Liu D., Tessier A., Hutchison, and Murray D. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 89 (2000) 453-457
36. Temmink O.H., Hoebe E.K., van der born K., Fukushima M., and Peters G.J. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. Br J Cancer 96 (2007) 231-240
37. Arnould S., Hennebelle I., Canal P., Bugat R., and Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cells. Eur J Cancer 39 (2002) 112-119
38. Galm O., fabry U., Efferth T., and Osieka R. Synergism between rViscumin and cisplatin is not dependent on ERCC-1 expression. Cancer Lett 187 (2002) 143-151
39. Hector S., Bolonowska-Higdon W., Zdanowicz j, Hitt S., and Pendyala L. In vitro studies on the mechanics of oxaliplatin resistance. Cancer Chemother Pharmacol 48 (2001) 398-406
40. Guichard S., Arnould S., Hennebelle I., Bugat R., and Canal P. Combination of oxaliplatin and irinotecan on human colon cancer cells lines: activity in vitro and in vivo. Anti-Cancer Drugs 12 (2001) 741-751
41. Hwang I.G., Ahn M.J., Park B.B., Park S., Lee S.C., Ahn Y.C., et al. ERCC1 expression as a predictive marker in stage IIIA, N2 positive non-small lung cancer patients treated with neoadjuvant concurrent chemoradiotherapy followed by surgery. J Thorac Oncol 2 (2007) S367
42. Fujii T., Toyooka S., Ichimura K., Fujiwara Y., Hotta K., and Soh J. ERCC1 predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer 08 (2007) 025